Project Grant R41AI149803

Novobiotic Pharmaceuticals, LLC received a $4.5 million Project Grant award from the Defense Health Agency to conduct late-stage preclinical development of the antibiotic teixobactin through April 2026. The funding supports research under the Military Medical Research and Development program, which aims to develop medical solutions for battlefield injuries and infectious diseases. Specifically, the award will allow Novobiotic to advance teixobactin, initially discovered using its iChip...

This $384,863 Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the "Discovery and Applied Research for Technological Innovations to Improve Human Health" (CFDA 93.286) program supports research to develop a novel radiotracer imaging agent for detecting Gram-positive bacterial infections associated with implanted medical devices. The key products and services to be delivered include: In vitro testing of a bivalent radiotracer agent...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,000,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Taxis Pharmaceuticals Inc. for the "Lead Optimization of Oral DHFR Inhibitor for the Treatment of Multidrug-Resistant N. Gonorrhoeae Infections" project. The grant supports the development of a new oral antibiotic to treat gonorrhea infections that have become resistant to existing therapies. The proposed...

The National Institutes of Health's National Institute of General Medical Sciences awarded Oragenics, Inc. a $769,962 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to support computer-aided design of novel lantibiotics with improved antibiotic properties from August 1, 2021 to July 31, 2022. Specifically, the awardee will investigate the molecular interaction between the lantibiotic mutacin 1140 and its target in silico to rank analogs, synthesize and...

This Project Grant award of $300,000 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research by Fimbrion Therapeutics Inc. to develop small molecule glycoside inhibitors targeting the LecB lectin protein in Pseudomonas aeruginosa (PA) bacteria. The goal is to create novel therapeutics to disrupt PA biofilm formation and enhance the efficacy of antibiotics in treating PA infections,...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Program (CFDA 93.855) is supporting research to develop a novel, water-soluble, cationic bolaamphiphile (CAB) platform nanocarrier complexed with an antisense oligonucleotide (ASO) targeting the essential C. difficile dnaE gene. The $426,875 award, which began on Jul 14, 2025 and runs through Jun 30, 2027, aims to advance this platform technology as a...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $314,363 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Via Therapeutics, LLC, a pharmaceutical research and development company based in Austin, Texas. The grant supports the development of an inhaled, fixed-dose combination powder product containing both azithromycin and amikacin for the treatment of non-tuberculous mycobacterial (NTM) infections. The goal is to improve...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded Vast Therapeutics, Inc. a $2,000,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a novel nitric oxide-releasing formulation (ALX1) for the treatment of Pseudomonas aeruginosa infections in bronchiectasis patients. The objective is to answer critical questions needed to initiate Phase II proof-of-concept clinical trials for this broad-spectrum antibacterial therapy,...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $300,000 in funding to Fimbrion Therapeutics Inc. in Missouri to develop an orally bioavailable thiazolino-pyridone (TZP) small molecule series with inhibitory activity against Mycobacterium tuberculosis. The goal is to create a first-in-class TZP compound that could become a novel drug for treating...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $298,582 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Microbiotix, Inc., a clinical-stage biopharmaceutical company in Worcester, MA. The grant supports the development of novel inhibitors to treat drug-resistant cytomegalovirus (CMV) infections, which are a major cause of morbidity and mortality in immunosuppressed patients, particularly transplant recipients. Microbiotix...